Glenmark Naproxen Sodium Tablets recalled for CGMP deviations
Glenmark Pharmaceuticals is recalling 9,552 bottles of Naproxen Sodium Tablets USP 275 mg nationwide due to CGMP (current Good Manufacturing Practice) deviations identified at the manufacturing facility.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for CGMP deviations. The source text does not report any illnesses, injuries, or adverse events; the hazard is compliance-related manufacturing practice, not product harm. Per the rubric, Class II recalls without reported illness or injury are rated 2 (Moderate).
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Naproxen Sodium Tablets, USP 275 mg (100 tablets per bottle, NDC 68462-178-01) due to CGMP deviations. The recall affects 9,552 bottles distributed nationwide.
The affected lots are: 29190087 (Exp. 10/31/2021), 29190088 (Exp. 10/31/2021), 29190089 (Exp. 10/31/2021), 29200077 (Exp. 11/30/2022), and 29200078 (Exp. 11/30/2022). The product is manufactured by Glenmark Pharmaceuticals Inc., USA at 4147 Goldmine Road, Monroe, NC 28110.
The recall is voluntary and was initiated by the firm on August 27, 2021, following FDA notification of CGMP deviations at the manufacturing facility. This is a Class II recall. Patients taking this medication should consult their healthcare provider or pharmacist about whether to continue use or obtain replacement product from an alternative source.
The recalled product
- Product
- NAPROXEN SODIUM (NAPROXEN SODIUM)
- Brand
- NAPROXEN SODIUM
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription NSAID
- Affected units
- 9,552
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots: 29190087 Exp. 10/31/2021
- 29190088 Exp. 10/31/2021
- 29190089 Exp. 10/31/2021
- 29200077 Exp. 11/30/2022
- 29200078 Exo
- 11/30/2022
UPCs (5)
- 0368462189016
- 0368462178010
- 0368462179017
- 0368462188019
- 0368462190012
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same brand · NAPROXEN SODIUM
- ModerateNaproxen Sodium tablets recalled due to manufacturing compliance deviations
FDA (Drugs) · 2025-04-16
- HighPrescription Naproxen 250mg tablets recalled for labeling mix-up with indomethacin
FDA (Drugs) · 2023-12-06
- ModerateGlenmark Naproxen Sodium 550 mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2021-09-29
- ModerateGlenmark Recalls Naproxen Sodium Tablets Due to Labeling Error
FDA (Drugs) · 2012-10-03
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19